Should combination therapy be the paradigm for future nonalcoholic steatohepatitis clinical trials?
Open Access
- 27 September 2011
- journal article
- editorial
- Published by Ovid Technologies (Wolters Kluwer Health) in Hepatology
- Vol. 54 (5), 1503-1505
- https://doi.org/10.1002/hep.24696
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: A 12-month randomized, prospective, open- label trialHepatology, 2011
- Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and AdolescentsPublished by American Medical Association (AMA) ,2011
- Endpoints and clinical trial design for nonalcoholic steatohepatitisHepatology, 2011
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic SteatohepatitisThe New England Journal of Medicine, 2010
- A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver diseaseHepatology, 2010
- Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitisHepatology, 2009
- Effect of Losartan, an Angiotensin II Antagonist, on Hepatic Fibrosis Induced by CCl4in RatsDigestive Diseases and Sciences, 2004
- Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitisHepatology, 2004
- AT1A-deficient mice show less severe progression of liver fibrosis induced by CCl4Biochemical and Biophysical Research Communications, 2003
- Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertensionJournal of Hepatology, 2002